Detection of KRAS, NRAS and BRAF mutations in liquid biopsy
from patients with colorectal cancer

Přehled o publikaci

J 2026

Detection of KRAS, NRAS and BRAF mutations in liquid biopsy from patients with colorectal cancer

ONDRÁŠKOVÁ, Kateřina; Matouš CWIK; Ondřej HORKÝ; Jitka BERKOVCOVÁ; Jitka HOLČÁKOVÁ et al.

Basic information

Original name

Detection of KRAS, NRAS and BRAF mutations in liquid biopsy from patients with colorectal cancer

Authors

ONDRÁŠKOVÁ, Kateřina; Matouš CWIK; Ondřej HORKÝ; Jitka BERKOVCOVÁ; Jitka HOLČÁKOVÁ; Martin BARTOŠÍK; Tomáš KAZDA; Klára MRÁZOVÁ; Michal UHER; Igor KISS and Roman HRSTKA

Edition

ONCOLOGY RESEARCH, COGNIZANT COMMUNICATION CORP, 2026, 0965-0407

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Marked to be transferred to RIV

Organization

Přírodovědecká fakulta – Repository – Repository

Keywords (in Czech)

tekutá biopsie; kolorektální karcinom; kapénková digitální PCR (ddPCR); mutace protoonkogenu Kirstenova virového sarkomu potkana (KRAS)

Keywords in English

Liquid biopsy; colorectal cancer (CRC); droplet digital PCR (ddPCR); Kirsten Rat Sarcoma Viral Proto- Oncogene (KRAS) mutation

Links

BBMRI.cz IV, large research infrastructures.

Changed: 6/3/2026 00:51, RNDr. Daniel Jakubík

Abstract

In the original language

Objectives: Cancer treatment relies heavily on accurate diagnosis and effective monitoring of the disease. These processes often involve invasive procedures, such as colonoscopy, to detect malignant tissues, followed by molecular analyses to determine relevant biomarkers. This study aimed to evaluate the clinical performance of droplet digital PCR (ddPCR) for detecting Kirsten Rat Sarcoma Viral Proto-Oncogene (KRAS), Neuroblastoma RAS Viral Oncogene Homolog (NRAS), and B-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations in circulating tumor DNA (ctDNA) from colorectal cancer patients using liquid biopsy. Methods: ctDNA was isolated from colorectal cancer (CRC) patients (n = 110) and analyzed for KRAS, BRAF, and NRAS mutations. The ctDNA obtained through liquid biopsy was analyzed using ddPCR, and the findings were compared with sequencing data from tumor DNA archived in formalin-fixed paraffin-embedded (FFPE) blocks. Results: For KRAS mutations, ddPCR achieved a sensitivity of 72.0% and a specificity of 71.4%. However, when pooling all target mutations (KRAS, NRAS and BRAF), the overall sensitivity and specificity were lower, at 48.3% and 51.1%, respectively. Conclusion: The results of this study indicate that the ddPCR analysis of ctDNA may provide complementary information for the molecular diagnosis of CRC patients.

Files attached

https://is.muni.cz/publication/2546661/2546661.pdf

Cite

ONDRÁŠKOVÁ, Kateřina; Matouš CWIK; Ondřej HORKÝ; Jitka BERKOVCOVÁ; Jitka HOLČÁKOVÁ; Martin BARTOŠÍK; Tomáš KAZDA; Klára MRÁZOVÁ; Michal UHER; Igor KISS and Roman HRSTKA. Detection of KRAS, NRAS and BRAF mutations in liquid biopsy from patients with colorectal cancer. ONCOLOGY RESEARCH. COGNIZANT COMMUNICATION CORP, 2026, vol. 34, No 2, p. 1-10, 27 pp. ISSN 0965-0407. Available from: https://doi.org/10.32604/or.2025.070116.

@article{102711,
   author = {Ondrášková, Kateřina and Cwik, Matouš and Horký, Ondřej and Berkovcová, Jitka and Holčáková, Jitka and Bartošík, Martin and Kazda, Tomáš and Mrázová, Klára and Uher, Michal and Kiss, Igor and Hrstka, Roman},
   article_number = {2},
   doi = {https://doi.org/10.32604/or.2025.070116},
   keywords = {Liquid biopsy; colorectal cancer (CRC); droplet digital PCR (ddPCR); Kirsten Rat Sarcoma Viral Proto- Oncogene (KRAS) mutation},
   language = {eng},
   issn = {0965-0407},
   journal = {ONCOLOGY RESEARCH},
   title = {Detection of KRAS, NRAS and BRAF mutations in liquid biopsy from patients with colorectal cancer},
   url = {https://pubmed.ncbi.nlm.nih.gov/41613815/},
   volume = {34},
   year = {2026}
}

TY  - JOUR
ID  - 102711
AU  - Ondrášková, Kateřina - Cwik, Matouš - Horký, Ondřej - Berkovcová, Jitka - Holčáková, Jitka - Bartošík, Martin - Kazda, Tomáš - Mrázová, Klára - Uher, Michal - Kiss, Igor - Hrstka, Roman
PY  - 2026
TI  - Detection of KRAS, NRAS and BRAF mutations in liquid biopsy from patients with colorectal cancer
JF  - ONCOLOGY RESEARCH
VL  - 34
IS  - 2
SP  - 1-10
EP  - 1-10
PB  - COGNIZANT COMMUNICATION CORP
SN  - 0965-0407
KW  - Liquid biopsy
KW  - colorectal cancer (CRC)
KW  - droplet digital PCR (ddPCR)
KW  - Kirsten Rat Sarcoma Viral Proto- Oncogene (KRAS) mutation
UR  - https://pubmed.ncbi.nlm.nih.gov/41613815/
N2  - Objectives: Cancer treatment relies heavily on accurate diagnosis and effective monitoring of the disease. These processes often involve invasive procedures, such as colonoscopy, to detect malignant tissues, followed by molecular analyses to determine relevant biomarkers. This study aimed to evaluate the clinical performance of droplet digital PCR (ddPCR) for detecting Kirsten Rat Sarcoma Viral Proto-Oncogene (KRAS), Neuroblastoma RAS Viral Oncogene Homolog (NRAS), and B-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations in circulating tumor DNA (ctDNA) from colorectal cancer patients using liquid biopsy. Methods: ctDNA was isolated from colorectal cancer (CRC) patients (n = 110) and analyzed for KRAS, BRAF, and NRAS mutations. The ctDNA obtained through liquid biopsy was analyzed using ddPCR, and the findings were compared with sequencing data from tumor DNA archived in formalin-fixed paraffin-embedded (FFPE) blocks. Results: For KRAS mutations, ddPCR achieved a sensitivity of 72.0% and a specificity of 71.4%. However, when pooling all target mutations (KRAS, NRAS and BRAF), the overall sensitivity and specificity were lower, at 48.3% and 51.1%, respectively. Conclusion: The results of this study indicate that the ddPCR analysis of ctDNA may provide complementary information for the molecular diagnosis of CRC patients.
ER  -

ONDRÁŠKOVÁ, Kateřina; Matouš CWIK; Ondřej HORKÝ; Jitka BERKOVCOVÁ; Jitka HOLČÁKOVÁ; Martin BARTOŠÍK; Tomáš KAZDA; Klára MRÁZOVÁ; Michal UHER; Igor KISS and Roman HRSTKA. Detection of KRAS, NRAS and BRAF mutations in liquid biopsy from patients with colorectal cancer. \textit{ONCOLOGY RESEARCH}. COGNIZANT COMMUNICATION CORP, 2026, vol.~34, No~2, p.~1-10, 27 pp. ISSN~0965-0407. Available from: https://doi.org/10.32604/or.2025.070116.

Přehled o publikaci